The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

VOV.VN - The Ho Chi Minh City Department of Health has withdrawn 70 registrations for medical devices after uncovering ...

DNV, the independent assurance and risk management provider, has been recognized by the European Commission as a notified ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio enables early detection of amyloid plaques through a non-invasive blood ...

The U.S. Food and Drug Administration (USFDA) has cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer's disease. The Lumipulse ...

The Europe in vitro diagnostics (IVD) market has showcased significant growth, with its valuation increasing from $13,825 million in 2019 to an anticipated $18,647 million by 2027. This report ...

In order to ensure the safety and efficacy of medical devices entering its Member States, the European Union (EU) has ...

This report analyzes in vitro diagnostic (IVD) technologies and devices used in hospitals and point-of-care (POC) settings, focusing on market trends, drivers, opportunities, and competitive ...

The FDA has cleared the first-ever blood test for early Alzheimer's detection, which the agency says reduces the need for ...